Open AccessCabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
Author(s) -
М. И. Волкова,
Я. В. Гриднева,
А. С. Ольшанская
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-10-146-154
Subject(s) - cabazitaxel , prostate cancer , docetaxel , medicine , oncology , abiraterone , refractory (planetary science) , cancer , androgen receptor , pharmacology , androgen deprivation therapy , biology , astrobiology
Cabazitaxel, an antineoplastic agent from the third generation taxan group, has demonstrated efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. This article is devoted to a critical analysis of studies on the use of cabazitaxel in this category of patients and key aspects of management of treatment-related toxicity. The authors also reviewed possible scenarios for the use of cabazitaxel in the sequential therapy of mCRPC, including androgen receptor signalling inhibitors and systemic radiotherapy.